Treatment of Urgency Urinary Incontinence Aids Sleep Quality

Share this content:
Treatment of Urgency Urinary Incontinence Aids Sleep Quality
Treatment of Urgency Urinary Incontinence Aids Sleep Quality

FRIDAY, Jan. 12, 2018 (HealthDay News) -- Pharmacologic treatment of urgency urinary incontinence (UUI) improves sleep quality, according to research published online Jan. 9 in Obstetrics & Gynecology.

Qurratul A. Warsi, M.B.B.S., from University of California, San Francisco, and colleagues conducted planned secondary data analysis of sleep outcomes in a previously conducted multicenter, randomized trial of pharmacologic therapy for urgency-predominant incontinence among 645 community-dwelling women. Incontinence symptoms and a sleep assessment were conducted at baseline and 12 weeks.

The researchers found that, at baseline, 57 percent of women had poor sleep quality (Pittsburgh Sleep Quality Index score of >5). At study follow-up, women randomized to the antimuscarinic group reported a greater decrease in UUI frequency (P < 0.001) and diurnal and nocturnal voiding frequency (P < 0.05), compared the placebo group. The antimuscarinic group also reported greater improvement in sleep quality (total Pittsburgh Sleep Quality Index score of 0.48; P = 0.02), with greater improvement in sleep duration and sleep efficiency subscales (P < 0.05). Daytime sleepiness was not affected.

"Pharmacologic treatment of UUI is associated with decreased incontinence frequency and nocturia and improvement in overall sleep quality, sleep duration, and sleep efficiency," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which provided study medication.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »